BioSante Sees No Adverse Effect On LibiGel From Flibanserin Review
Executive Summary
The FDA advisory committee setback for Boehringer Ingelheim's hypoactive sexual desire disorder drug Girosa (flibanserin) has given a lift to BioSante Pharmaceuticals, which believes its testosterone gel LibiGel is now positioned to be the first approved treatment for HSDD